CytoSMART Launches Its 1st Fluorescence Live-cell Imaging Microscope

November 3, 2020

CytoSMART Technologies today announced its first fluorescence live-cell imager. The CytoSMART Lux3 FL is a small live-cell imaging microscope equipped with one brightfield and two fluorescent channels (green and red).

CytoSMART notes the device enables researchers to unravel cellular processes in real-time, while the cells are kept in a controlled environment inside a standard cell culture incubator.

CytoSMART states their first fluorescence live-cell imager allows users to track dynamic cellular processes with high specificity by taking high-quality images to create real-time time-lapse movies.


Said Jan-Willem van Bree, CTO at CytoSMART Technologies, “Currently, fluorescent labeling is mostly used as an end-point measurement. However, time-lapse imaging of live cells can give much more information about biological processes. By using automated imaging at regular time intervals, the temporal resolution of the fluorescent data is increased, leading to even more relevant data about the cellular processes.

In this way, researchers can not only determine if a certain process has occurred, but also when it occurred and at what speed. Our customers have been asking us to develop a small and easy-to-use microscope with integrated image analysis of bright-field and fluorescence data. We have listened and made it happen.”

The main features and benefits of the CytoSMART Lux3 FL include:

  • Integrated image analysis of bright-field and fluorescence area or fluorescence object count.
  • Time-lapse movies to investigate the development of cellular processes.
  • Expanded number of variables researchers can analyze in their cell culture using green and red fluorescence.
  • Remote data accessibility via the CytoSMART Cloud with a smartphone, tablet, or laptop outside the lab.
  • Portable, easy-to-use, and incubator friendly live-cell imager.

 

SourceCytoSMART

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”